Selma TOSUN, Şebnem ÇALIK, Sibel ÖZSU YILMAZ, Alpay ARI

A persistently low HBV DNA level is a predictor of spontaneous HBsAg clearance in patients with chronic hepatitis B

Bckground/aim: The incidence and predictors of spontaneous hepatitis B surface-antigen (HBsAg) seroclearance in patients with chronic hepatitis B virus (HBV) were evaluated. Materials and methods: A total of 1427 patients with chronic HBV infection, who were followed between 1994 and 2013, were investigated in this retrospective study. All data were extracted from patient files. Results: Spontaneous HBsAg seroclearance occurred in 84 patients during 8798 person-years of follow-up. The patients were categorized into 3 groups at follow-up based on HBV DNA features as continuously 10,000 copies/mL (Group C). Alanine aminotransferase features in the 2 groups were categorized as continuously normal (40 U/L. Spontaneous HBsAg seroclearance was seen primarily in patients with Group A HBV DNA features, and continuously low HBV DNA values were the main predictor of HBsAg seroclearance (P < 0.001). Conclusion: These results suggest that a continuously low viral load is the most important factor affecting spontaneous HBsAg seroclearance.

PDF

___

1. WHO (2014). Hepatitis B Fact Sheet. Geneva, Switzerland: WHO; 2014.
2. He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M , Zhu P, Huang H, Wang Y. Long-term outcomes after nucleos(t) ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis 2013; 13: 458.
3. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133 143.
4. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigennegative patients with a low viral load. Hepatology 2012; 55: 6876.
5. Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011; 204: 408414.
6. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187 1192.
7. Yalçın K, Değertekin H, Alp MN, Tekeş S, Satıcı O, Budak T. Determination of serum hepatitis B virus DNA in chronic HBsAg carriers: clinical significance and correlation with serological markers. Turk J Gastroenterol 2003; 14: 157 163.
8. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J 2005; 2: 8287.
9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167185.
10. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661662.
11. Sunbul M, Leblebicioglu H. Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. World J Gastroenterol 2005; 11: 19761980.
12. Furusyo N, Hayashi J, Sawayama Y, Kishihara Y, Kashiwagi S. Hepatitis B surface antigen disappearance and hepatitis B surface antigen subtype: a prospective, long-term, followup study of Japanese residents of Okinawa, Japan with chronic hepatitis B virus infection. Am J Trop Med Hyg 1999; 60: 616622.